The synergy of Quercetin and Bromelain creates a powerful, multi-functional supplement ideal for supporting immunity, respiratory comfort and systemic inflammation. Whether addressing seasonal allergies, post-exercise inflammation or seeking long-term immune and cardiovascular support, lipolife® delivers these potent nutrients in their most bioavailable form.
Encapsulated using the proprietary SAIFx® liposomal technology, this formula ensures enhanced absorption and maximum bioavailability at the cellular level.
This expertly developed supplement supports:
- Immune and Inflammatory Response:
Quercetin is a plant-derived flavonoid renowned for its ability to modulate the body’s immune and inflammatory responses. It works by stabilising mast cells, regulating histamine release, and inhibiting pro-inflammatory enzymes such as COX and LOX. When delivered in a liposomal format, the notoriously low bioavailability of quercetin is dramatically improved, allowing it to circulate more effectively throughout the body for optimal benefit. - Respiratory and Allergy Support:
Bromelain, a proteolytic enzyme extracted from pineapple, has natural anti-inflammatory and mucolytic properties. It helps to break down and clear excess mucus, making it highly beneficial for respiratory health and seasonal allergy symptoms. Bromelain also enhances the absorption of quercetin and contributes to immune regulation and tissue repair. - Cardiovascular and Antioxidant Protection:
Together, Quercetin and Bromelain provide robust antioxidant support, protecting cells from oxidative damage and supporting endothelial function. This combination is particularly useful in promoting healthy circulation, reducing vascular inflammation, and supporting blood vessel integrity, key components of cardiovascular health and healthy ageing.
lipolife® offer a scientifically advanced, liposomal formulation combining Quercetin and Bromelain to support immune function, manage inflammation and promote respiratory and cardiovascular health.


Reviews
There are no reviews yet.